The general approach should be a combination of rituximab and chemotherapy, traditionally using alkylating agents, with or without an anthracycline, with more recent evidence for the alternative ...

The study, published in JACC: CardioOncology, demonstrates that treatment with the SGLT2 inhibitor empagliflozin can mitigate the cardiac injury associated with anthracycline therapy ...